Novel adjuvant teases T cells to respond to HCV
Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response.
First drug found to reduce COVID-19-mortality
A clinical trial has identified the first immuno-modulatory drug to significantly reduce COVID-19 mortality in ventilated patients.
Germany puts 300m in CureVac AG for COVID-19 vaccine
In the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG.
Abbvie and Genmab team up in oncology
AbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats.
Evox Therapeutics signs US$1.2bn deal with Eli Lilly
Evox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases.
Calliditas Therapeutics raise US$90m in Nasdaq IPO
Swedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO.
Hyloris Pharmaceuticals prepared to go public
Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
NodThera bags US$55m in Series B round
NodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
Bacterial colonisation differs by tumour type
An analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.
Novo Holdings invests into AI CRO ExScientia